Slide 1: Coloplast Earnings Conference Call H1 2017/18
Coloplast Earnings Conference Call H1 2017/18 3 May 2018
Slide 2: Forward-looking statements
Forward-looking statements The forward-looking statements contained in this presentation, including forecasts of sales and earnings performance, are not guarantees of future results and are subject to risks, uncertainties and assumptions that are difficult to predict. The forward-looking statements
Slide 3: Coloplast delivered Q2 organic growth of 8% and upgrades FY organic growth guidance
Coloplast delivered Q2 organic growth of 8% and upgrades FY organic growth guidance from ~7% to 7-8% Revenue growth Q2 Highlights +8% • Q2 organic growth of 8% (4% in DKK) Reported revenue (DKKm) +5% • Negative FX impact from USD/DKK. Acquisitions contributed 1% Organic growth +8% 7,990 to growth 7,
Slide 4: 8% organic growth in H1 driven by strong momentum in all business areas except Wound & Skin Care
8% organic growth in H1 driven by strong momentum in all business areas except Wound & Skin Care H1 17/18 revenue by business area H1 17/18 revenue by geography Business Reported revenue Organic growth Share of organic Geographic Reported revenue Organic growth Share of organic area DKKm growth area
Slide 5: H1 17/18 revenue significantly impacted by the depreciation of USD and USD related currencies against DKK
H1 17/18 revenue significantly impacted by the depreciation of USD and USD related currencies against DKK Comments Revenue development • H1 2017/18 reported revenue increased by DKK (DKKm) 82 8,316 354m or 5% compared to H1 2016/17 -326 7,990 • The majority of growth was driven by organic 598 growth
Slide 6: H1 EBIT margin dilution due to increased commercial investments across business areas and regions
H1 EBIT margin dilution due to increased commercial investments across business areas and regions EBIT margin development (%) Comments • EBIT fell 3% to DKK 2,407m with a reported margin of 30% (31% 32.4 in constant currencies) compared to 32% last year -1.0 • Gross margin of 67% compared to 68% sam
Slide 7: Upgraded organic and reported growth guidance for FY 2017/18
Upgraded organic and reported growth guidance for FY 2017/18 Guidance 2017/18 Guidance 2017/18 (DKK)* Key assumptions • Negative impact of DKK 50m from patent expiry • More than 1% negative price pressure of which DKK 7-8% from ~7% ~6% from 5-6% 100m from price reform in Greece Sales growth • DKK gu
Slide 8: Our mission, values and vision
Our mission Making life easier for peoplé with intimate healthcare needs Our values Closeness... to better understand. - Passion... to make a difference Respect and responsibility... to 0 guide | US: Our vision Setting the global standard for listening and responding: Coloplast A/S - Ostomy Care / C